Floatz logo

Therapeutic Asset Ratings

6,305 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
anv419
Metastatic Melanoma
Anaveon AGP1/2CC (46)
Apg 115
Myelodysplastic Syndrome
Ascentage Pharma Group Inc.P1/2CC (46)
ARG
Lymphoma
ITM Solucin GmbHP1/2CC (46)
Aro-Mmp7 Inhalation
Idiopathic Pulmonary Fibrosis
Arrowhead PharmaceuticalsP1/2CC (46)
Avelumab
Gastroesophageal Cancer
Fate TherapeuticsP1/2CC (46)
Avutometinib
Cancer
Verastem, Inc.P1/2CC (46)
Avutometinib
Glioblastoma
Institute of Cancer Research, United KingdomP1/2CC (46)
Avutometinib
Metastatic Malignant Neoplasm
Verastem, Inc.P1/2CC (46)
Baricitinib
Amyotrophic Lateral Sclerosis
Massachusetts General HospitalP1/2CC (46)
Baricitinib
Cognitive Disorder
Massachusetts General HospitalP1/2CC (46)
Butyrin
Parkinson Disease
Prabesh KanelP1/2CC (46)
Bxq-350
Peripheral Neuropathy
Bexion Pharmaceuticals, Inc.P1/2CC (46)
Byon5667
Breast Cancer
Byondis B.V.P1/2CC (46)
Cabozantinib
Gastric Cancer
Anwaar SaeedP1/2CC (46)
Cambritaxestat
Malignant Pancreatic Neoplasm
iOncturaP1/2CC (46)
cd19-ucart
Mantle Cell Lymphoma
University of Colorado, DenverP1/2CC (46)
cd70-targeting car-t cells
Lymphoma
St. Jude Children's Research HospitalP1/2CC (46)
Cea Car-T Cells
Gastric Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea Car-T Cells
Lung Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea-Targeted Car-T
Colon Carcinoma
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea-Targeted Car-T
Esophageal Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea-Targeted Car-T
Gastric Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea-Targeted Car-T
Lung Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cetrelimab
Non-Small Cell Lung Carcinoma
Ankyra Therapeutics, IncP1/2CC (46)
Cmtx-101
Cystic Fibrosis
Clarametyx Biosciences, Inc.P1/2CC (46)
Showing 2751 to 2775 of 6,305 assets
PreviousPage 111 of 253Next